Skip to content

Study · Systematic review · n = 1,529 · 2011

3 results

A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research.

MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ

Psychoneuroendocrinology23 Mar 2011Cited by 276 (Europe PMC)

PMID21429671 (opens in a new tab)DOI10.1016/j.psyneuen.2011.02.015 (opens in a new tab)PepBankPUB-21429671
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In a systematic review of intranasal oxytocin trials, side effects did not differ between oxytocin and placebo.

    In plain wordsIn a review of trials, nasal oxytocin caused no more side effects than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSide effects versus placebo
    Study

    n = 1,529

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    18-40 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Side effects are not different between oxytocin and placebo
    2 context sentences
    Summary · context
    Since 1990, research trials have reported on N=1529 (79% male) of which 8% were participants with developmental or mental health difficulties.
    Summary · context
    A systematic review of 38 randomised controlled trials conducted between 1990 and 2010 that investigated the central effects of intranasal oxytocin was undertaken.
  2. 02HumanSystematic reviewSafety outcome

    In a systematic review of intranasal oxytocin trials, participants could not accurately report whether they had received oxytocin or placebo.

    In plain wordsIn a review of trials, people could not tell whether they got nasal oxytocin or placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeParticipants' ability to tell oxytocin from placebo
    Study

    n = 1,529

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    18-40 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    participants are unable to accurately report on whether they have received oxytocin and placebo.
    2 context sentences
    Summary · context
    Since 1990, research trials have reported on N=1529 (79% male) of which 8% were participants with developmental or mental health difficulties.
    Summary · context
    A systematic review of 38 randomised controlled trials conducted between 1990 and 2010 that investigated the central effects of intranasal oxytocin was undertaken.
  3. 03HumanSystematic reviewSafety outcome

    The review found three case reports of adverse reactions due to misuse and longer-term use of intranasal oxytocin.

    In plain wordsThe review found three case reports of harmful reactions from misuse or longer-term use of nasal oxytocin.

    Peptide
    Oxytocin
    Outcome
    Not applicableAdverse reactions in case reports of misuse or longer-term use
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Three case reports of adverse reactions due to misuse and longer-term use of intranasal oxytocin were reported.
    1 context sentence
    Summary · context
    A systematic review of 38 randomised controlled trials conducted between 1990 and 2010 that investigated the central effects of intranasal oxytocin was undertaken.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials8

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

8 trials · 6 completed · 2 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT06945926

The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery

Zhejiang Universityn = 2271 Jun 2025 to 2 Jun 2026

Cervical Spinal Stenosis · Thoracic Spinal Stenosis · Lumbar Spinal Stenosis · Rotator Cuff Injury · Femoral Head Necrosis · Spinal Trauma · Knee Joint Injury

Trial pageClinicalTrials.govUpdated 20 Aug 2026
CompletedPhase 1NCT03060031

Effects of Intranasal Oxytocin Administration on Social Influence Effects on Pain

University of Colorado, Bouldern = 5121 Jun 2017 to 1 Apr 2019

Pain

Trial pageClinicalTrials.govUpdated 25 Jun 2019
CompletedNot applicableNCT03114371

Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years

University Hospital, Toulousen = 4028 Nov 2016 to 11 Jan 2019

Prader-Willi Syndrome

Trial pageClinicalTrials.govUpdated 12 Nov 2020
CompletedPhase 4Results postedNCT02550093

The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold

Northwestern Universityn = 20Apr 2015 to Nov 2016

Healthy

Trial pageClinicalTrials.govUpdated 16 May 2022
SuspendedEarly phase 1NCT02091817

The Effect of Oxytocin on Face Perception

Soroka University Medical Centern = 100Nov 2013 to est. Dec 2017

Healthy · Congenital Prosopagnosia

Trial pageClinicalTrials.govUpdated 2 Jul 2015
WithdrawnPhase 1NCT01912378

Triadic Interactions of Families With Autism and Oxytocin

University of California, San Franciscon = 0Aug 2013 to May 2015

Autism Disorder

Trial pageClinicalTrials.govUpdated 16 Jan 2019
CompletedPhase 1Results postedNCT01834261

Brain Dynamics of Oxytocin

Stony Brook Universityn = 51Apr 2013 to May 2015

Brain Dynamics in Healthy Adults

Trial pageClinicalTrials.govUpdated 17 Mar 2017
CompletedEarly phase 1Results postedNCT01780337

Oxytocin Effects on Cardiac Electrophysiology

William Whangn = 12Jan 2013 to May 2016

Cardiac Arrhythmia

Trial pageClinicalTrials.govUpdated 21 Jul 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.